인벤티지랩
Financials
Valuation Metrics
인벤티지랩's Market Cap is ₩3347B. At end of 2025 it was ₩1.1T. Ranked #613 of 2,421 in KR market (top 25%), #251 of 1,640 on KOSDAQ (top 15%), #63 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 27%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 334.69B KRW | KR#613/2,421 Sec#63/231 |
| Revenue | 2.47B KRW | KR#2,377/2,421 Sec#210/231 |
| Net Income | -10.77B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 194.14B KRW | KR#1,335/2,421 Sec#97/231 |
| Net Assets | 111.08B KRW | KR#1,338/2,421 Sec#106/231 |
| Employees | 69 | KR#1,887/2,421 Sec#163/231 |
| Value | ||
| P/B | 3.01x | KR#2,109/2,421 Sec#167/231 |
| P/S | 135.35x | KR#2,397/2,421 Sec#214/231 |
| FCF Yield | -7.74% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -9.69% | KR#1,929/2,421 Sec#145/231 |
| ROA | -5.55% | KR#1,957/2,421 Sec#142/231 |
| Op. Margin | -1359.73% | KR#2,384/2,421 Sec#216/231 |
| Revenue Growth | 6.06% | KR#1,133/2,421 Sec#112/231 |
| Financial Health | ||
| Debt Ratio | 74.77% | KR#1,276/2,421 Sec#152/231 |
| Total Debt | 28.93B KRW | KR#1,246/2,421 Sec#97/231 |
| FCF | -25.89B KRW | KR#1,955/2,421 Sec#188/231 |
| Cash | 97.59B KRW | KR#478/2,421 Sec#24/231 |
| Current Ratio | 2.86x | KR#596/2,421 Sec#79/231 |
| Performance | ||
| 1Y Return | -49.19% | KR#2,043/2,421 Sec#185/231 |
| 1M Return | -16.45% | KR#2,271/2,421 Sec#199/231 |
| From 52W High | -75.27% | KR#2,294/2,421 Sec#202/231 |
| 1Y MDD | -75.73% | KR#2,204/2,421 Sec#196/231 |
| Trading | ||
| Volume | 73,919 shares | KR#942/2,421 Sec#98/231 |
| Trading Value | 1.89B KRW | KR#566/2,421 Sec#55/231 |
| Foreign Own. | 10.99% | KR#441/2,421 Sec#35/231 |
| Per Share | ||
| EPS | -809 KRW | KR—/2,421 Sec—/231 |
| BPS | 8,347 KRW | KR#1,105/2,421 Sec#78/231 |
Company Info
Inventis Lab was established in 2015, and in 2025, it acquired KOSDAQ-listed Curatis, securing a mass production base for long-acting injectable drugs and gene therapy/mRNA vaccines. It possesses an IVL platform that applies microfluidic technology to drug research and development, providing long-acting injectable drug development and LNP manufacturing services. The company has license agreements with domestic and international pharmaceutical companies and is expanding clinical trial material production and CDMO business through manufacturing facilities in Curatis' GMP factory. Inventis Lab is headquartered in Seongnam-si, Gyeonggi-do.